Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Sale Of Rx Allergy Drugs Would Be Safer, Cut Costs - Health Plan

This article was originally published in The Tan Sheet

Executive Summary

Nonsedating antihistamines classified as prescription drugs would be more appropriately sold as OTCs, Blue Cross of California Pharmacy VP Rob Seidman maintains in Jan. 12 letters sent to marketers of the drugs.

You may also be interested in...



Rx Label Use Permissible Even If FDA Finds Drug Is Safe OTC – Attorney

A drug sponsor may create and use alternative labeling saying it requires prescription distribution for a medicine even if FDA has determined the drug does not need to be limited to the Rx arena, according to attorney Andrew Krulwich of the Washington, D.C.-based law firm Wiley, Rein & Fielding

Rx Label Use Permissible Even If FDA Finds Drug Is Safe OTC – Attorney

A drug sponsor may create and use alternative labeling saying it requires prescription distribution for a medicine even if FDA has determined the drug does not need to be limited to the Rx arena, according to attorney Andrew Krulwich of the Washington, D.C.-based law firm Wiley, Rein & Fielding

Rx Label Use Permissible Even If FDA Finds Drug Is Safe OTC – Attorney

A drug sponsor may create and use alternative labeling saying it requires prescription distribution for a medicine even if FDA has determined the drug does not need to be limited to the Rx arena, according to attorney Andrew Krulwich of the Washington, D.C.-based law firm Wiley, Rein & Fielding

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel